LGVN / Longeveron: Speculative Biotech Worth A Look On Rare Disease, Aging, And Alzheimer's Focuses

Longeveron Inc. shares LGVN, +4.58% jumped 16% premarket on Thursday after the clinical-stage biotech company announced positive results from a trial more_horizontal

Longeveron Inc. (NASDAQ:LGVN ) Q2 2023 Earnings Conference Call August 11, 2023 8:00 AM ET Company Participants Mike Moyer - Managing Director, LifeSc more_horizontal

Longeveron Inc. (NASDAQ:LGVN ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants James Clavijo - Chief Financial Officer W more_horizontal

Longeveron (NASDAQ: LGVN ) just reported results for the first quarter of 2023. Longeveron reported a loss per share of 22 cents. more_horizontal

Longeveron (NASDAQ: LGVN ) stock is on the move Tuesday after releasing long-term survival data from its HLHS treatment. According to the company, al more_horizontal

Longeveron Inc.'s stock LGVN rocketed 15.5% in premarket trade Tuesday, after the biotech said its Lomecel-B for the treatment of a congenital heart d more_horizontal

Longeveron Inc. (NASDAQ:LGVN ) Q4 2022 Results Conference Call March 10, 2023 8:30 AM ET Company Participants James Clavijo - CFO Wa'el Hashad - CEO D more_horizontal

Live conference call on Friday, March 10 at 8:30 a.m. ET Live conference call on Friday, March 10 at 8:30 a.m. ET more_horizontal